Skip to content
OpenCapital
Get started

Organon OGN Cash & Equivalents

Cash & Equivalents at other companies

Pfizer logo
PfizerPFE
$1.76B+18.8%
Amgen logo
AmgenAMGN
$559M+10.0%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$139M+19.6%
Biogen logo
BiogenBIIB
$3.38B+30.2%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$197.66M+234%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%
Enterprise value$10.98B-26.4%
P/E6.6×+2.1×
P/S0.6×-0.8×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's cash & equivalents?
Organon (OGN) reported cash & equivalents of $1.12B in Q1 2026.
How has Organon's cash & equivalents changed year-over-year?
Organon's cash & equivalents increased by 104.0% year-over-year, from $547M to $1.12B.
What is the long-term trend for Organon's cash & equivalents?
Over 5 years (2020 to 2025), Organon's cash & equivalents has grown at a 116.7% compound annual growth rate (CAGR), from $12M to $574M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.